Noncoding RNA in age-related cardiovascular diseases

Journal of Molecular and Cellular Cardiology

Volumn 83, Issue , 2015, Pages 142-155

  Greco, Simona ^a   Gorospe, Myriam ^b   Martelli, Fabio ^a  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Aging; Cardiovascular disease; Long noncoding RNA; MicroRNA

Indexed keywords

LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 132; MICRORNA 217; SIRTUIN 1; UNCLASSIFIED DRUG; UNTRANSLATED RNA; SIRT1 PROTEIN, HUMAN;

AGING; AUTOPHAGY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CORONARY ARTERY DISEASE; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART FAILURE; HEART INFARCTION; HOMEOSTASIS; HUMAN; OXIDATIVE STRESS; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; RNA TRANSPORT; SENESCENCE; AGED; ANIMAL; BLOOD VESSEL; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

EUKARYOTA;

AGED; AGING; ANIMALS; BLOOD VESSELS; CORONARY ARTERY DISEASE; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MYOCARDIAL INFARCTION; MYOCARDIUM; RNA, UNTRANSLATED; SIGNAL TRANSDUCTION; SIRTUIN 1; TRANSCRIPTION, GENETIC;

EID: 84937694780     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.01.011     Document Type: Review

References (214)

1. Cech T.R., Steitz J.A. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 2014, 157:77-94.
2. Salmanidis M., Pillman K., Goodall G., Bracken C. Direct transcriptional regulation by nuclear microRNAs. Int J Biochem Cell Biol 2014, 54c:304-311.
3. Yoon J.H., Abdelmohsen K., Gorospe M. Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol 2013, 425:3723-3730.
4. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010, 11:597-610.
5. Djebali S., Davis C.A., Merkel A., Dobin A., Lassmann T., Mortazavi A., et al. Landscape of transcription in human cells. Nature 2012, 489:101-108.
6. Li L., Chang H.Y. Physiological roles of long noncoding RNAs: insight from knockout mice. Trends Cell Biol 2014, 24:594-602.
7. Small E.M., Olson E.N. Pervasive roles of microRNAs in cardiovascular biology. Nature 2011, 469:336-342.
8. Chen L.H., Chiou G.Y., Chen Y.W., Li H.Y., Chiou S.H. MicroRNA and aging: a novel modulator in regulating the aging network. Ageing Res Rev 2010, 9(Suppl. 1):S59-S66.
9. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010, 79:351-379.
10. Ha M., Kim V.N. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014, 15:509-524.
11. Gorospe M., Abdelmohsen K. MicroRegulators come of age in senescence. Trends Genet 2011, 27:233-241.
12. Jansson M.D., Lund A.H. MicroRNA and cancer. Mol Oncol 2012, 6:590-610.
13. Fiore R., Siegel G., Schratt G. MicroRNA function in neuronal development, plasticity and disease. Biochim Biophys Acta 2008, 1779:471-478.
14. Kung J.T., Colognori D., Lee J.T. Long noncoding RNAs: past, present, and future. Genetics 2013, 193:651-669.
15. Spitale R.C., Tsai M.C., Chang H.Y. RNA templating the epigenome: long noncoding RNAs as molecular scaffolds. Epigenetics 2011, 6:539-543.
16. Lee J.T. Epigenetic regulation by long noncoding RNAs. Science 2012, 338:1435-1439.
17. Bergmann J.H., Spector D.L. Long non-coding RNAs: modulators of nuclear structure and function. Curr Opin Cell Biol 2014, 26:10-18.
18. Gong C., Maquat L.E. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. Nature 2011, 470:284-288.
19. Yoon J.H., Abdelmohsen K., Srikantan S., Yang X., Martindale J.L., De S., et al. LincRNA-p21 suppresses target mRNA translation. Mol Cell 2012, 47:648-655.
20. Mattick J.S. Long noncoding RNAs in cell and developmental biology. Semin Cell Dev Biol 2011, 22:327.
21. Anko M.L., Neugebauer K.M. Long noncoding RNAs add another layer to pre-mRNA splicing regulation. Mol Cell 2010, 39:833-834.
22. Cesana M., Cacchiarelli D., Legnini I., Santini T., Sthandier O., Chinappi M., et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147:358-369.
23. Tay Y., Rinn J., Pandolfi P.P. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014, 505:344-352.
24. Yoon J.H., Abdelmohsen K., Kim J., Yang X., Martindale J.L., Tominaga-Yamanaka K., et al. Scaffold function of long non-coding RNA HOTAIR in protein ubiquitination. Nat Commun 2013, 4:2939.
25. Wapinski O., Chang H.Y. Long noncoding RNAs and human disease. Trends Cell Biol 2011, 21:354-361.
26. Harries L.W. Long non-coding RNAs and human disease. Biochem Soc Trans 2012, 40:902-906.
27. Mozaffarian D., Afshin A., Benowitz N.L., Bittner V., Daniels S.R., Franch H.A., et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation 2012, 126:1514-1563.
28. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
29. Shioi T., Inuzuka Y. Aging as a substrate of heart failure. J Cardiol 2012, 60:423-428.
30. Dai D.F., Rabinovitch P.S., Ungvari Z. Mitochondria and cardiovascular aging. Circ Res 2012, 110:1109-1124.
31. Csiszar A., Ungvari Z., Edwards J.G., Kaminski P., Wolin M.S., Koller A., et al. Aging-induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 2002, 90:1159-1166.
32. Lakatta E.G. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part III: cellular and molecular clues to heart and arterial aging. Circulation 2003, 107:490-497.
33. Gimbrone M.A., Topper J.N., Nagel T., Anderson K.R., Garcia-Cardena G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000, 902:230-239. [discussion 9-40].
34. Ungvari Z., Sonntag W.E., Csiszar A. Mitochondria and aging in the vascular system. J Mol Med 2010, 88:1021-1027.
35. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
36. Lee H.Y., Oh B.H. Aging and arterial stiffness. Circ J 2010, 74:2257-2262.
37. Kato M., Slack F.J. Ageing and the small, non-coding RNA world. Ageing Res Rev 2013, 12:429-435.
38. Harries L.W. MicroRNAs as mediators of the ageing process. Genes 2014, 5:656-670.
39. Zhang X., Azhar G., Wei J.Y. The expression of microRNA and microRNA clusters in the aging heart. PLoS ONE 2012, 7:e34688.
40. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965, 37:614-636.
41. Kuilman T., Michaloglou C., Mooi W.J., Peeper D.S. The essence of senescence. Genes Dev 2010, 24:2463-2479.
42. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522.
43. Rodier F., Campisi J. Four faces of cellular senescence. J Cell Biol 2011, 192:547-556.
44. Tyner S.D., Venkatachalam S., Choi J., Jones S., Ghebranious N., Igelmann H., et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002, 415:45-53.
45. Baker D.J., Wijshake T., Tchkonia T., LeBrasseur N.K., Childs B.G., van de Sluis B., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479:232-236.
46. Fenton M., Barker S., Kurz D.J., Erusalimsky J.D. Cellular senescence after single and repeated balloon catheter denudations of rabbit carotid arteries. Arterioscler Thromb Vasc Biol 2001, 21:220-226.
47. Minamino T., Miyauchi H., Yoshida T., Ishida Y., Yoshida H., Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002, 105:1541-1544.
48. Abdelmohsen K., Kuwano Y., Kim H.H., Gorospe M. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence. Biol Chem 2008, 389:243-255.
49. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
50. Borgdorff V., Lleonart M.E., Bishop C.L., Fessart D., Bergin A.H., Overhoff M.G., et al. Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1). Oncogene 2010, 29:2262-2271.
51. Marasa B.S., Srikantan S., Masuda K., Abdelmohsen K., Kuwano Y., Yang X., et al. Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs. Sci Signal 2009, 2:ra69.
52. Afanasyeva E.A., Mestdagh P., Kumps C., Vandesompele J., Ehemann V., Theissen J., et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ 2011, 18:974-984.
53. Boon R.A., Seeger T., Heydt S., Fischer A., Hergenreider E., Horrevoets A.J., et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 2011, 109:1115-1119.
54. Olivieri F., Lazzarini R., Recchioni R., Marcheselli F., Rippo M.R., Di Nuzzo S., et al. MiR-146a as marker of senescence-associated pro-inflammatory status in cells involved in vascular remodelling. Age (Dordr) 2013, 35:1157-1172.
55. Olivieri F., Spazzafumo L., Santini G., Lazzarini R., Albertini M.C., Rippo M.R., et al. Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging. Mech Ageing Dev 2012, 133:675-685.
56. Asgeirsdottir S.A., van Solingen C., Kurniati N.F., Zwiers P.J., Heeringa P., van Meurs M., et al. MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. Am J Physiol Renal Physiol 2012, 302:F1630-F1639.
57. Fukushima Y., Nakanishi M., Nonogi H., Goto Y., Iwai N. Assessment of plasma miRNAs in congestive heart failure. Circ J 2011, 75:336-340.
58. Feng X., Wang H., Ye S., Guan J., Tan W., Cheng S., et al. Up-regulation of microRNA-126 may contribute to pathogenesis of ulcerative colitis via regulating NF-kappaB inhibitor IkappaBalpha. PLoS ONE 2012, 7:e52782.
59. Wei Y., Nazari-Jahantigh M., Neth P., Weber C., Schober A. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?. Arterioscler Thromb Vasc Biol 2013, 33:449-454.
60. Kim S., Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000, 52:11-34.
61. Boon R.A., Iekushi K., Lechner S., Seeger T., Fischer A., Heydt S., et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013, 495:107-110.
62. Bradshaw A.D., Baicu C.F., Rentz T.J., Van Laer A.O., Bonnema D.D., Zile M.R. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am J Physiol Heart Circ Physiol 2010, 298:H614-H622.
63. Burgess M.L., McCrea J.C., Hedrick H.L. Age-associated changes in cardiac matrix and integrins. Mech Ageing Dev 2001, 122:1739-1756.
64. Swinnen M., Vanhoutte D., Van Almen G.C., Hamdani N., Schellings M.W., D'Hooge J., et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 2009, 120:1585-1597.
65. Wang M., Zhang J., Walker S.J., Dworakowski R., Lakatta E.G., Shah A.M. Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol 2010, 48:765-772.
66. St John Sutton M., Pfeffer M.A., Moye L., Plappert T., Rouleau J.L., Lamas G., et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997, 96:3294-3299.
67. Gould K.E., Taffet G.E., Michael L.H., Christie R.M., Konkol D.L., Pocius J.S., et al. Heart failure and greater infarct expansion in middle-aged mice: a relevant model for postinfarction failure. Am J Physiol Heart Circ Physiol 2002, 282:H615-H621.
68. Minamino T., Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res 2007, 100:15-26.
69. van Almen G.C., Verhesen W., van Leeuwen R.E., van de Vrie M., Eurlings C., Schellings M.W., et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011, 10:769-779.
70. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
71. Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009, 104:170-178. [6p following 8].
72. Oldham S. Obesity and nutrient sensing TOR pathway in flies and vertebrates: Functional conservation of genetic mechanisms. Trends Endocrinol Metab 2011, 22:45-52.
73. Curtis B., Lage M.J. Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study. J Med Econ 2014, 17:21-31.
74. Bornfeldt K.E. 2013 Russell Ross memorial lecture in vascular biology: cellular and molecular mechanisms of diabetes mellitus-accelerated atherosclerosis. Arterioscler Thromb Vasc Biol 2014, 34:705-714.
75. Yu Q., Gao F., Ma X.L. Insulin says NO to cardiovascular disease. Cardiovasc Res 2011, 89:516-524.
76. Cersosimo E., DeFronzo R.A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006, 22:423-436.
77. Curtis R., Geesaman B.J., DiStefano P.S. Ageing and metabolism: drug discovery opportunities. Nat Rev Drug Discov 2005, 4:569-580.
78. Yu X.Y., Song Y.H., Geng Y.J., Lin Q.X., Shan Z.X., Lin S.G., et al. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. Biochem Biophys Res Commun 2008, 376:548-552.
79. Elia L., Contu R., Quintavalle M., Varrone F., Chimenti C., Russo M.A., et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009, 120:2377-2385.
80. Shan Z.X., Lin Q.X., Fu Y.H., Deng C.Y., Zhou Z.L., Zhu J.N., et al. Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun 2009, 381:597-601.
81. Li Y., Higashi Y., Itabe H., Song Y.H., Du J., Delafontaine P. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol 2003, 23:2178-2184.
82. Delafontaine P., Brink M. The growth hormone and insulin-like growth factor 1 axis in heart failure. Ann Endocrinol 2000, 61:22-26.
83. Ungvari Z., Parrado-Fernandez C., Csiszar A., de Cabo R. Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging. Circ Res 2008, 102:519-528.
84. Valcarcel-Ares M.N., Gautam T., Warrington J.P., Bailey-Downs L., Sosnowska D., de Cabo R., et al. Disruption of Nrf2 signaling impairs angiogenic capacity of endothelial cells: implications for microvascular aging. J Gerontol A: Biol Med Sci 2012, 67:821-829.
85. Green D.R., Galluzzi L., Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011, 333:1109-1112.
86. Napoli C., de Nigris F., Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem 2001, 82:674-682.
87. Tsutsui H., Kinugawa S., Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol 2011, 301:H2181-H2190.
88. Magenta A., Greco S., Gaetano C., Martelli F. Oxidative stress and microRNAs in vascular diseases. Int J Mol Sci 2013, 14:17319-17346.
89. Magenta A., Cencioni C., Fasanaro P., Zaccagnini G., Greco S., Sarra-Ferraris G., et al. miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 2011, 18:1628-1639.
90. Zaccagnini G., Martelli F., Fasanaro P., Magenta A., Gaetano C., Di Carlo A., et al. p66ShcA modulates tissue response to hindlimb ischemia. Circulation 2004, 109:2917-2923.
91. Baseler W.A., Thapa D., Jagannathan R., Dabkowski E.R., Croston T.L., Hollander J.M. miR-141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1 diabetic heart. Am J Physiol Cell Physiol 2012, 303:C1244-C1251.
92. Pulakat L., Aroor A.R., Gul R., Sowers J.R. Cardiac insulin resistance and microRNA modulators. Exp Diabetes Res 2012, 2012:654904.
93. Lin Y., Liu X., Cheng Y., Yang J., Huo Y., Zhang C. Involvement of MicroRNAs in hydrogen peroxide-mediated gene regulation and cellular injury response in vascular smooth muscle cells. J Biol Chem 2009, 284:7903-7913.
94. Hulsmans M., Holvoet P. The vicious circle between oxidative stress and inflammation in atherosclerosis. J Cell Mol Med 2010, 14:70-78.
95. Weber M., Baker M.B., Moore J.P., Searles C.D. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity. Biochem Biophys Res Commun 2010, 393:643-648.
96. Fleissner F., Jazbutyte V., Fiedler J., Gupta S.K., Yin X., Xu Q., et al. Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res 2010, 107:138-143.
97. Li R., Yan G., Li Q., Sun H., Hu Y., Sun J., et al. MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H(2)O(2))-induced apoptosis through targeting the mitochondria apoptotic pathway. PLoS ONE 2012, 7:e44907.
98. Greco S., Gaetano C., Martelli F. HypoxamiR regulation and function in ischemic cardiovascular diseases. Antioxid Redox Signal 2014, 21:1202-1219.
99. Zaccagnini G., Maimone B., Di Stefano V., Fasanaro P., Greco S., Perfetti A., et al. Hypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia. Antioxid Redox Signal 2014, 21:1177-1188.
100. Martinet W., De Meyer G.R. Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential. Circ Res 2009, 104:304-317.
101. Cuervo A.M. Autophagy and aging: keeping that old broom working. Trends Genet 2008, 24:604-612.
102. Kang H.T., Lee K.B., Kim S.Y., Choi H.R., Park S.C. Autophagy impairment induces premature senescence in primary human fibroblasts. PLoS ONE 2011, 6:e23367.
103. Menghini R., Casagrande V., Marino A., Marchetti V., Cardellini M., Stoehr R., et al. MiR-216a: a link between endothelial dysfunction and autophagy. Cell Death Dis. 2014, 5:e1029.
104. Rogina B., Helfand S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc Natl Acad Sci U S A 2004, 101:15998-16003.
105. Bordone L., Guarente L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat Rev Mol Cell Biol 2005, 6:298-305.
106. Schwer B., Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab 2008, 7:104-112.
107. Potente M., Dimmeler S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle 2008, 7:2117-2122.
108. Dhahbi J.M., Spindler S.R., Atamna H., Yamakawa A., Guerrero N., Boffelli D., et al. Deep sequencing identifies circulating mouse miRNAs that are functionally implicated in manifestations of aging and responsive to calorie restriction. Aging 2013, 5:130-141.
109. Menghini R., Casagrande V., Cardellini M., Martelli E., Terrinoni A., Amati F., et al. MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation 2009, 120:1524-1532.
110. Zhang L., Huang D., Wang Q., Shen D., Wang Y., Chen B., et al. MiR-132 inhibits expression of SIRT1 and induces pro-inflammatory processes of vascular endothelial inflammation through blockade of the SREBP-1c metabolic pathway. Cardiovasc Drugs Ther 2014, 28:303-311.
111. Ponugoti B., Kim D.H., Xiao Z., Smith Z., Miao J., Zang M., et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 2010, 285:33959-33970.
112. Kumarswamy R., Volkmann I., Beermann J., Napp L.C., Jabs O., Bhayadia R., et al. Vascular importance of the miR-212/132 cluster. Eur Heart J 2014, 35:3224-3231.
113. Guarani V., Deflorian G., Franco C.A., Kruger M., Phng L.K., Bentley K., et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature 2011, 473:234-238.
114. Ito T., Yagi S., Yamakuchi M. MicroRNA-34a regulation of endothelial senescence. Biochem Biophys Res Commun 2010, 398:735-740.
115. Xu Q., Seeger F.H., Castillo J., Iekushi K., Boon R.A., Farcas R., et al. Micro-RNA-34a contributes to the impaired function of bone marrow-derived mononuclear cells from patients with cardiovascular disease. J Am Coll Cardiol 2012, 59:2107-2117.
116. Tabuchi T., Satoh M., Itoh T., Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci (Lond) 2012, 123:161-171.
117. Zhu H., Yang Y., Wang Y., Li J., Schiller P.W., Peng T. MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovasc Res 2011, 92:75-84.
118. Rane S., He M., Sayed D., Vashistha H., Malhotra A., Sadoshima J., et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1alpha and Sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ Res 2009, 104:879-886.
119. Abdelmohsen K., Panda A., Kang M.J., Xu J., Selimyan R., Yoon J.H., et al. Senescence-associated lncRNAs: senescence-associated long noncoding RNAs. Aging Cell 2013, 12:890-900.
120. Abdelmohsen K., Panda A.C., Kang M.J., Guo R., Kim J., Grammatikakis I., et al. 7SL RNA represses p53 translation by competing with HuR. Nucleic Acids Res 2014, 42:10099-10111.
121. Tripathi V., Shen Z., Chakraborty A., Giri S., Freier S.M., Wu X., et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 2013, 9:e1003368.
122. Hewitt G., Jurk D., Marques F.D., Correia-Melo C., Hardy T., Gackowska A., et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun 2012, 3:708.
123. Bernardes de Jesus B., Vera E., Schneeberger K., Tejera A.M., Ayuso E., Bosch F., et al. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med 2012, 4:691-704.
124. Redon S., Zemp I., Lingner J. A three-state model for the regulation of telomerase by TERRA and hnRNPA1. Nucleic Acids Res 2013, 41:9117-9128.
125. Wang K., Liu F., Zhou L.Y., Long B., Yuan S.M., Wang Y., et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489. Circ Res 2014, 114:1377-1388.
126. Liu H., Song G., Zhou L., Hu X., Liu M., Nie J., et al. Compared analysis of LncRNA expression profiling in pdk1 gene knockout mice at two time points. Cell Physiol Biochem 2013, 32:1497-1508.
127. Ravingerova T., Barancik M., Strniskova M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 2003, 247:127-138.
128. Wang Y., Su B., Sah V.P., Brown J.H., Han J., Chien K.R. Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells. J Biol Chem 1998, 273:5423-5426.
129. Podlowski S., Bramlage P., Baumann G., Morano I., Luther H.P. Cardiac troponin I sense-antisense RNA duplexes in the myocardium. J Cell Biochem 2002, 85:198-207.
130. Annilo T., Kepp K., Laan M. Natural antisense transcript of natriuretic peptide precursor A (NPPA): structural organization and modulation of NPPA expression. BMC Mol Biol 2009, 10:81.
131. Horsthuis T., Houweling A.C., Habets P.E., de Lange F.J., el Azzouzi H., Clout D.E., et al. Distinct regulation of developmental and heart disease-induced atrial natriuretic factor expression by two separate distal sequences. Circ Res 2008, 102:849-859.
132. Han P., Li W., Lin C.H., Yang J., Shang C., Nuernberg S.T., et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature 2014, 514:102-106.
133. Eagle K.A., Nallamothu B.K., Mehta R.H., Granger C.B., Steg P.G., Van de Werf F., et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J 2008, 29:609-617.
134. Windecker S., Bax J.J., Myat A., Stone G.W., Marber M.S. Future treatment strategies in ST-segment elevation myocardial infarction. Lancet 2013, 382:644-657.
135. White H.D., Chew D.P. Acute myocardial infarction. Lancet 2008, 372:570-584.
136. Liu Y., Li G., Lu H., Li W., Li X., Liu H., et al. Expression profiling and ontology analysis of long noncoding RNAs in post-ischemic heart and their implied roles in ischemia/reperfusion injury. Gene 2014, 543:15-21.
137. Zangrando J., Zhang L., Vausort M., Maskali F., Marie P.Y., Wagner D.R., et al. Identification of candidate long non-coding RNAs in response to myocardial infarction. BMC Genomics 2014, 15:460.
138. Broadbent H.M., Peden J.F., Lorkowski S., Goel A., Ongen H., Green F., et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet 2008, 17:806-814.
139. Cugino D., Gianfagna F., Santimone I., de Gaetano G., Donati M.B., Iacoviello L., et al. Type 2 diabetes and polymorphisms on chromosome 9p21: a meta-analysis. Nutr Metab Cardiovasc Dis 2012, 22:619-625.
140. Jeck W.R., Siebold A.P., Sharpless N.E. Review: a meta-analysis of GWAS and age-associated diseases. Aging Cell 2012, 11:727-731.
141. Holdt L.M., Teupser D. From genotype to phenotype in human atherosclerosis-recent findings. Curr Opin Lipidol 2013, 24:410-418.
142. Holdt L.M., Teupser D. Recent studies of the human chromosome 9p21 locus, which is associated with atherosclerosis in human populations. Arterioscler Thromb Vasc Biol 2012, 32:196-206.
143. Holdt L.M., Beutner F., Scholz M., Gielen S., Gabel G., Bergert H., et al. ANRIL expression is associated with atherosclerosis risk at chromosome 9p21. Arterioscler Thromb Vasc Biol 2010, 30:620-627.
144. Holdt L.M., Hoffmann S., Sass K., Langenberger D., Scholz M., Krohn K., et al. Alu elements in ANRIL non-coding RNA at chromosome 9p21 modulate atherogenic cell functions through trans-regulation of gene networks. PLoS Genet 2013, 9:e1003588.
145. Cortez M.A., Calin G.A. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9:703-711.
146. Huang X., Yuan T., Tschannen M., Sun Z., Jacob H., Du M., et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 2013, 14:319.
147. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
148. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 2008, 3:e3694.
149. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
150. Gilad S., Meiri E., Yogev Y., Benjamin S., Lebanony D., Yerushalmi N., et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008, 3:e3148.
151. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
152. van Empel V.P., De Windt L.J., da Costa Martins P.A. Circulating miRNAs: reflecting or affecting cardiovascular disease?. Curr Hypertens Rep 2012, 14:498-509.
153. Gupta S.K., Bang C., Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ. Cardiovasc. Genet. 2010, 3:484-488.
154. Xu J., Zhao J., Evan G., Xiao C., Cheng Y., Xiao J. Circulating microRNAs: novel biomarkers for cardiovascular diseases. J Mol Med 2012, 90:865-875.
155. da Silva AM Gomes, Silbiger V.N. miRNAs as biomarkers of atrial fibrillation. Biomarkers 2014, 1-6.
156. Zampetaki A., Willeit P., Drozdov I., Kiechl S., Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012, 93:555-562.
157. Fasanaro P., D'Alessandra Y., Magenta A., Pompilio G., Capogrossi M.C. MicroRNAs: promising biomarkers and therapeutic targets of acute myocardial ischemia. Curr Vasc Pharmacol 2013.
158. Di Stefano V., Zaccagnini G., Capogrossi M.C., Martelli F. microRNAs as peripheral blood biomarkers of cardiovascular disease. Vasc Pharmacol 2011, 55:111-118.
159. D'Alessandra Y., Devanna P., Limana F., Straino S., Di Carlo A., Brambilla P.G., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010, 31:2765-2773.
160. Chen X., Liang H., Zhang J., Zen K., Zhang C.Y. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 2012, 22:125-132.
161. Loyer X., Vion A.C., Tedgui A., Boulanger C.M. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res 2014, 114:345-353.
162. Ren J., Zhang J., Xu N., Han G., Geng Q., Song J., et al. Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS ONE 2013, 8:e80738.
163. Wang G.K., Zhu J.Q., Zhang J.T., Li Q., Li Y., He J., et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010, 31:659-666.
164. Sayed A.S., Xia K., Yang T.L., Peng J. Circulating microRNAs: a potential role in diagnosis and prognosis of acute myocardial infarction. Dis Markers 2013, 35:561-566.
165. Cui J., Zhao N. Consideration in selection of the control group in diagnostic tests. Int J Biol Sci 2012, 8:1418-1419.
166. Olivieri F., Antonicelli R., Lorenzi M., D'Alessandra Y., Lazzarini R., Santini G., et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol 2013, 167:531-536.
167. Olivieri F., Antonicelli R., Spazzafumo L., Santini G., Rippo M.R., Galeazzi R., et al. Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. Int J Cardiol 2014, 172:e276-e278.
168. Thum T., Mayr M. Review focus on the role of microRNA in cardiovascular biology and disease. Cardiovasc Res 2012, 93:543-544.
169. Fichtlscherer S., Zeiher A.M., Dimmeler S. Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?. Arterioscler Thromb Vasc Biol 2011, 31:2383-2390.
170. D'Alessandra Y., Carena M.C., Spazzafumo L., Martinelli F., Bassetti B., Devanna P., et al. Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. PLoS ONE 2013, 8:e80345.
171. Hoekstra M., van der Lans C.A., Halvorsen B., Gullestad L., Kuiper J., Aukrust P., et al. The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun 2010, 394:792-797.
172. Tijsen A.J., Creemers E.E., Moerland P.D., de Windt L.J., van der Wal A.C., Kok W.E., et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010, 106:1035-1039.
173. Corsten M.F., Dennert R., Jochems S., Kuznetsova T., Devaux Y., Hofstra L., et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet. 2010, 3:499-506.
174. Voellenkle C., van Rooij J., Cappuzzello C., Greco S., Arcelli D., Di Vito L., et al. MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients. Physiol Genomics 2010, 42:420-426.
175. Caporali A., Meloni M., Vollenkle C., Bonci D., Sala-Newby G.B., Addis R., et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011, 123:282-291.
176. Dhahbi J.M., Kim H.J., Mote P.L., Beaver R.J., Spindler S.R. Temporal linkage between the phenotypic and genomic responses to caloric restriction. Proc Natl Acad Sci U S A 2004, 101:5524-5529.
177. Pollack M., Phaneuf S., Dirks A., Leeuwenburgh C. The role of apoptosis in the normal aging brain, skeletal muscle, and heart. Ann N Y Acad Sci 2002, 959:93-107.
178. Higami Y., Shimokawa I. Apoptosis in the aging process. Cell Tissue Res 2000, 301:125-132.
179. Vausort M., Wagner D.R., Devaux Y. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res 2014, 115:668-677.
180. Li D., Chen G., Yang J., Fan X., Gong Y., Xu G., et al. Transcriptome analysis reveals distinct patterns of long noncoding RNAs in heart and plasma of mice with heart failure. PLoS ONE 2013, 8:e77938.
181. Kumarswamy R., Bauters C., Volkmann I., Maury F., Fetisch J., Holzmann A., et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res 2014, 114:1569-1575.
182. He X., He L., Hannon G.J. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007, 67:11099-11101.
183. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
184. Wheeler T.M., Leger A.J., Pandey S.K., MacLeod A.R., Nakamori M., Cheng S.H., et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012, 488:111-115.
185. Takahashi H., Carninci P. Widespread genome transcription: new possibilities for RNA therapies. Biochem Biophys Res Commun 2014, 452:294-301.
186. Kaufmann K.B., Buning H., Galy A., Schambach A., Grez M. Gene therapy on the move. EMBO Mol Med 2013, 5:1642-1661.
187. Verma I.M., Weitzman M.D. Gene therapy: twenty-first century medicine. Annu Rev Biochem 2005, 74:711-738.
188. Greco S., Fasanaro P., Castelvecchio S., D'Alessandra Y., Arcelli D., Di Donato M., et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 2012, 61:1633-1641.
189. Lee J.H., Gao C., Peng G., Greer C., Ren S., Wang Y., et al. Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res 2011, 109:1332-1341.
190. Ritter O., Haase H., Schulte H.D., Lange P.E., Morano I. Remodeling of the hypertrophied human myocardium by cardiac bHLH transcription factors. J Cell Biochem 1999, 74:551-561.
191. Ai J., Zhang R., Li Y., Pu J., Lu Y., Jiao J., et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010, 391:73-77.
192. Cheng Y., Tan N., Yang J., Liu X., Cao X., He P., et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin Sci (Lond) 2010, 119:87-95.
193. Gidlof O., Andersson P., van der Pals J., Gotberg M., Erlinge D. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011, 118:217-226.
194. Li Y.Q., Zhang M.F., Wen H.Y., Hu C.L., Liu R., Wei H.Y., et al. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics (Sao Paulo) 2013, 68:75-80.
195. Wang R., Li N., Zhang Y., Ran Y., Pu J. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. Intern Med J 2011, 50:1789-1795.
196. Long G., Wang F., Duan Q., Yang S., Chen F., Gong W., et al. Circulating miR-30a, miR-195 and let-7b associated with acute myocardial infarction. PLoS ONE 2012, 7:e50926.
197. Long G., Wang F., Duan Q., Chen F., Yang S., Gong W., et al. Human circulating microRNA-1 and microRNA-126 as potential novel indicators for acute myocardial infarction. Int J Biol Sci 2012, 8:811-818.
198. Fichtlscherer S., De Rosa S., Fox H., Schwietz T., Fischer A., Liebetrau C., et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010, 107:677-684.
199. Hullinger T.G., Montgomery R.L., Seto A.G., Dickinson B.A., Semus H.M., Lynch J.M., et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 2012, 110:71-81.
200. Chen J., Huang Z.P., Seok H.Y., Ding J., Kataoka M., Zhang Z., et al. mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts. Circ Res 2013, 112:1557-1566.
201. Fiedler J., Jazbutyte V., Kirchmaier B.C., Gupta S.K., Lorenzen J., Hartmann D., et al. MicroRNA-24 regulates vascularity after myocardial infarction. Circulation 2011, 124:720-730.
202. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008, 105:13027-13032.
203. Ren X.P., Wu J., Wang X., Sartor M.A., Qian J., Jones K., et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009, 119:2357-2366.
204. Eulalio A., Mano M., Dal Ferro M., Zentilin L., Sinagra G., Zacchigna S., et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012, 492:376-381.
205. van Rooij E., Sutherland L.B., Qi X., Richardson J.A., Hill J., Olson E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575-579.
206. Callis T.E., Pandya K., Seok H.Y., Tang R.H., Tatsuguchi M., Huang Z.P., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009, 119:2772-2786.
207. Montgomery R.L., Hullinger T.G., Semus H.M., Dickinson B.A., Seto A.G., Lynch J.M., et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124:1537-1547.
208. Ucar A., Gupta S.K., Fiedler J., Erikci E., Kardasinski M., Batkai S., et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 2012, 3:1078.
209. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618.
210. Pan Z., Sun X., Shan H., Wang N., Wang J., Ren J., et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 2012, 126:840-850.
211. Li R.C., Tao J., Guo Y.B., Wu H.D., Liu R.F., Bai Y., et al. In vivo suppression of microRNA-24 prevents the transition toward decompensated hypertrophy in aortic-constricted mice. Circ Res 2013, 112:601-605.
212. Huang Z.P., Chen J., Seok H.Y., Zhang Z., Kataoka M., Hu X., et al. MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res 2013, 112:1234-1243.
213. da Costa Martins P.A., Salic K., Gladka M.M., Armand A.S., Leptidis S., el Azzouzi H., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010, 12:1220-1227.
214. Ganesan J., Ramanujam D., Sassi Y., Ahles A., Jentzsch C., Werfel S., et al. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation 2013, 127:2097-2106.